Ratings by Evercore ISI (Josh Schimmer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Mirum Pharmaceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2025 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2025 | Compass Pathways | CMPS | Downgrade | In Line (Outperform) |
4.63 (13.26) |
186.39% | Details | |
| 5/2/2025 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2025 | Rallybio Corp. | RLYB | Downgrade | In Line (Outperform) |
0.25 (15.88) |
6252% | Details | |
| 2/19/2025 | Krystal Biotech | KRYS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2025 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2024 | Spero Therapeutics | SPRO | Downgrade | In Line (Outperform) |
0.99 (2.20) |
122.22% | Details | |
| 12/20/2024 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2024 | Cabaletta Bio Inc. | CABA | Downgrade | In Line (Outperform) |
2.31 (3.06) |
32.47% | Details | |
| 9/17/2024 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2024 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Akero Therapeutics | AKRO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2024 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2024 | Akero Therapeutics | AKRO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2024 | Krystal Biotech | KRYS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2024 | Krystal Biotech | KRYS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2024 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2023 | Ventyx Biosciences Inc | VTYX | Downgrade | In Line (Outperform) |
2.58 (14.00) |
442.64% | Details | |
| 10/27/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2023 | Akero Therapeutics | AKRO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/13/2023 | Akero Therapeutics | AKRO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2023 | Krystal Biotech | KRYS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2023 | Gossamer Bio Inc. | GOSS | Downgrade | In Line (Outperform) |
1.82 (0.17) |
-90.66% | Details | |
| 6/14/2023 | Chinook Therapeutics | KDNY | Downgrade | In Line (Outperform) |
37.87 (40.39) |
6.65% | Details | |
| 6/6/2023 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/22/2023 | Avidity Biosciences | RNA | Upgrade | Outperform (In Line) |
10.82 (12.91) |
19.32% | Details | |
| 5/1/2023 | TG Therapeutics | TGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2023 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 4/19/2023 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
15.15 (69.92) |
361.52% | Details | |
| 4/18/2023 | BELLUS Health Inc. | BLU | Downgrade | In Line (Outperform) |
7.26 (14.74) |
103.03% | Details | |
| 3/31/2023 | Avidity Biosciences | RNA | Downgrade | In Line (Outperform) |
16.80 (12.91) |
-23.15% | Details | |
| 3/30/2023 | Atreca Inc. | BCEL | Downgrade | In Line (Outperform) |
1.28 (0.09) |
-92.97% | Details | |
| 3/24/2023 | Heron Therapeutics | HRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2023 | Zymeworks | ZYME | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2023 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2023 | Neurocrine Bio. | NBIX | Upgrade | Outperform (In Line) |
100.16 (165.74) |
65.48% | Details | |
| 3/1/2023 | PMV Pharmaceuticals Inc. | PMVP | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2023 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 2/16/2023 | Cabaletta Bio Inc. | CABA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/27/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/24/2023 | TG Therapeutics | TGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/29/2022 | TG Therapeutics | TGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2022 | Mirum Pharamceuticals | MIRM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2022 | MeiraGTx Holdings plc | MGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2022 | Erasca Inc | ERAS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2022 | Cabaletta Bio Inc. | CABA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2022 | Gossamer Bio Inc. | GOSS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | BELLUS Health Inc. | BLU | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2022 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2022 | Neurocrine Bio. | NBIX | Downgrade | In Line (Outperform) |
123.22 (165.74) |
34.51% | Details | |
| 11/9/2022 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2022 | DICE Therapeutics | DICE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/23/2022 | Spero Therapeutics | SPRO | Upgrade | Outperform (Underperform) |
0.82 (2.20) |
168.29% | Details | |
| 9/13/2022 | Akero Therapeutics | AKRO | Upgrade | Outperform (In Line) |
12.27 (54.74) |
346.13% | Details | |
| 8/9/2022 | Heron Therapeutics | HRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/29/2022 | Icosavax Inc. | ICVX | Upgrade | Outperform (In Line) |
8.42 (15.31) |
81.83% | Details | |
| 6/28/2022 | MeiraGTx Holdings plc | MGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/17/2022 | Inhibrx Inc. | INBX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Spero Therapeutics | SPRO | Downgrade | In Line (Outperform) |
5.09 (2.20) |
-56.78% | Details | |
| 4/26/2022 | Gossamer Bio Inc. | GOSS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/4/2022 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/1/2022 | Spero Therapeutics | SPRO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2022 | DICE Therapeutics | DICE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2022 | Icosavax Inc. | ICVX | Downgrade | In Line (Outperform) |
12.44 (15.31) |
23.07% | Details | |
| 3/22/2022 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2022 | Viracta Therapeutics | VIRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2022 | Rallybio Corp. | RLYB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2022 | Zymeworks | ZYME | New Coverage | Outperform (N/A) |
6.00 (24.48) |
308% | Details | |
| 2/24/2022 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2021 | BELLUS Health Inc. | BLU | Maintain | Outperform (N/A) |
|
Details | ||
| 12/1/2021 | TG Therapeutics | TGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2021 | Ventyx Biosciences Inc | VTYX | New Coverage | Outperform (N/A) |
22.97 (14.00) |
-39.05% | Details | |
| 10/12/2021 | Inhibrx Inc. | INBX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/11/2021 | DICE Therapeutics | DICE | New Coverage | Outperform (N/A) |
26.49 (47.55) |
79.5% | Details | |
| 9/7/2021 | Avidity Biosciences | RNA | New Coverage | Outperform (N/A) |
19.24 (12.91) |
-32.9% | Details | |
| 8/23/2021 | Rallybio Corp. | RLYB | New Coverage | Outperform (N/A) |
12.69 (0.25) |
-98.03% | Details | |
| 8/23/2021 | Icosavax Inc. | ICVX | New Coverage | Outperform (N/A) |
34.60 (15.31) |
-55.75% | Details | |
| 8/4/2021 | BeyondSpring Inc. | BYSI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2021 | Viracta Therapeutics | VIRX | New Coverage | Outperform (N/A) |
8.03 (0.08) |
-99% | Details | |
| 2/2/2021 | Cullinan Management | CGEM | New Coverage | Outperform (N/A) |
33.77 (18.28) |
-45.87% | Details | |
| 1/5/2021 | 4D Molecular Therapeutics | FDMT | New Coverage | Outperform (N/A) |
37.69 (11.51) |
-69.46% | Details | |
| 12/29/2020 | BeyondSpring Inc. | BYSI | New Coverage | Outperform (N/A) |
11.05 (1.63) |
-85.25% | Details | |
| 11/2/2020 | Chinook Therapeutics | KDNY | New Coverage | Outperform (N/A) |
12.35 (40.39) |
227.04% | Details | |
| 10/20/2020 | PMV Pharmaceuticals Inc. | PMVP | New Coverage | Outperform (N/A) |
37.46 (1.23) |
-96.72% | Details | |
| 9/29/2020 | Spero Therapeutics | SPRO | New Coverage | Outperform (N/A) |
9.30 (2.20) |
-76.34% | Details | |
| 9/14/2020 | Inhibrx Biosciences | INBX | New Coverage | Outperform (N/A) |
17.04 (95.07) |
457.92% | Details | |
| 9/1/2020 | Freeline | FRLN | New Coverage | Outperform (N/A) |
16.11 (6.48) |
-59.78% | Details | |
| 8/14/2020 | Altimmune | ALT | New Coverage | Outperform (N/A) |
23.70 (9.32) |
-60.68% | Details | |
| 8/4/2020 | Nkarta Inc. | NKTX | New Coverage | Outperform (N/A) |
26.58 (3.07) |
-88.45% | Details | |
| 6/4/2020 | Krystal Biotech | KRYS | New Coverage | Outperform (N/A) |
48.05 (350.24) |
628.91% | Details | |
| 5/12/2020 | CymaBay Therapeutic | CBAY | Upgrade | Outperform (In Line) |
1.78 (32.48) |
1724.72% | Details | |
| 12/20/2019 | Stealth BioTherapeutics | MITO | Downgrade | In Line (Outperform) |
13.70 (0.32) |
-97.66% | Details | |
| 12/17/2019 | Adamas Pharmaceuticals | ADMS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/25/2019 | CymaBay Therapeutic | CBAY | Downgrade | In Line (Outperform) |
5.55 (32.48) |
485.23% | Details | |
| 11/19/2019 | Cabaletta Bio Inc. | CABA | New Coverage | Outperform (N/A) |
13.79 (3.06) |
-77.81% | Details | |
| 8/12/2019 | Mirum Pharmaceuticals | MIRM | New Coverage | Outperform (N/A) |
14.77 (113.10) |
665.74% | Details | |
| 7/15/2019 | Akero Therapeutics | AKRO | New Coverage | Outperform (N/A) |
19.88 (54.74) |
175.35% | Details | |
| 6/11/2019 | CymaBay Therapeutic | CBAY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2019 | Ascendis Pharma | ASND | New Coverage | Outperform (N/A) |
123.22 (238.73) |
93.74% | Details | |
| 3/21/2019 | PolarityTE | PTE | New Coverage | Outperform (N/A) |
12.52 (0.24) |
-98.08% | Details | |
| 3/12/2019 | Stealth BioTherapeutics | MITO | New Coverage | Outperform (N/A) |
16.81 (13.70) |
-18.5% | Details | |
| 3/5/2019 | Gossamer Bio Inc. | GOSS | New Coverage | Outperform (N/A) |
23.00 (1.82) |
-92.09% | Details | |
| 2/25/2019 | Regenxbio Inc. | RGNX | Upgrade | Outperform (In Line) |
45.68 (10.96) |
-76.01% | Details | |
| 11/16/2018 | Madrigal Pharmaceuticals | MDGL | Upgrade | Outperform (In Line) |
132.71 (114.87) |
-13.44% | Details | |
| 9/19/2018 | ProQR Therapeutics N.V. | PRQR | New Coverage | Outperform (N/A) |
21.60 (1.43) |
-93.38% | Details |
